Scott Bahlavooni
About Scott Bahlavooni
Scott Bahlavooni is a Principal Clinical Programmer at Nektar Therapeutics, where he has worked since 2019. He has extensive experience in clinical programming, having held various roles at companies such as d-Wise Inc., Biogen, Genentech, and Quintiles.
Work at Nektar Therapeutics
Scott Bahlavooni has been serving as Principal Clinical Programmer at Nektar Therapeutics since 2019. In this role, he is responsible for overseeing clinical programming activities, ensuring compliance with regulatory standards, and contributing to the development of clinical trial protocols. His expertise in clinical programming supports the company's mission to advance innovative therapies.
Previous Experience in Clinical Programming
Prior to his current position, Scott Bahlavooni held several roles in the clinical programming field. He worked at d-Wise Inc. as a Senior Consultant from 2015 to 2018, where he provided consultancy services in clinical data management. Before that, he was a Principal Standards Analyst at Biogen from 2013 to 2015, focusing on data standards. His career began at Quintiles as a Clinical Programmer from 2001 to 2006, followed by a significant tenure at Genentech from 2006 to 2013 in the Data Standards Office.
Leadership Role at PhUSE
Scott Bahlavooni served as Co-Director of Working Groups on the PhUSE Board of Directors from 2017 to 2019. In this leadership role, he contributed to the development of industry standards and best practices in clinical data science. His involvement with PhUSE reflects his commitment to advancing the field of clinical programming and data management.
Education and Expertise
Scott Bahlavooni earned a Bachelor of Science degree in Mathematics and Statistics from Bloomsburg University of Pennsylvania. His educational background provides a strong foundation for his work in clinical programming, where analytical skills and statistical knowledge are essential for data analysis and interpretation in clinical trials.